Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia?

Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06040853
Collaborator
(none)
90
2
6

Study Details

Study Description

Brief Summary

Prostate cancer is the most diagnosed cancer among men today. Radical prostatectomy is a surgery that significantly reduces disease-related mortality. The laparoscopic technique, on the other hand, is preferred because it shortens the hospital stay, faster recovery and less postoperative pain.In this study, it was planned to investigate the analgesic or hyperalgesic effects of tranexamic acid, which is widely used in the management of bleeding in trauma, orthopedic, genitourinary and gynecological surgeries. Routine noninvasive monitoring (ECG, Spo2, NIBP) will be performed when participatient are taken to the operating table without premedication. After midazolam is administered, intubation will be performed by administering 1mg/kg lidocaine, 3mg/kg propofol, 2mcg/kg fentanyl, 0.6mg/kg rocuronium. Anesthesia will be maintained with desflurane with a MAC of 1. A 0.1-0.5 mcg/kg/min remifentanil infusion will be administered by targeting 40-60 values with BIS monitoring. After intubation, 15mg/kg tranexamic acid will be given 10 minutes before the incision, and 100 mg/h infusion will be administered until the skin is closed. The control group will be given 100 ml of saline.1mg/kg tramadol and 1gr parol will be administered 30 minutes before the end of the operation. The primary objectives of the study were to learn the VAS (Visual analog scale) score at 0.6,12, 24,48,72 hours, time to first analgesic requirement, and analgesic requirement within 24 hours. Secondary purposes are to determine the amount of antiemetic used, at the beginning of the operation, Hg at the first hour and postoperative 6 hours, complications and side effects (such as DVT, pulmonary embolism).

Condition or Disease Intervention/Treatment Phase
  • Drug: Tranexamic acid intravenous administration
  • Drug: Saline
Phase 4

Detailed Description

Prostate cancer is the most diagnosed cancer among men today. Radical prostatectomy is a surgery that significantly reduces disease-related mortality. The laparoscopic technique, on the other hand, is preferred because it shortens the hospital stay, faster recovery and less postoperative pain.In this study, it was planned to investigate the analgesic or hyperalgesic effects of tranexamic acid, which is widely used in the management of bleeding in trauma, orthopedic, genitourinary and gynecological surgeries

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Evaluation of Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia?
Anticipated Study Start Date :
Sep 30, 2023
Anticipated Primary Completion Date :
Feb 28, 2024
Anticipated Study Completion Date :
Mar 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: tranexamic group

After intubation, intravenous 15mg/kg tranexamic acid will be given to the study group 10 minutes before the incision and 100 mg/h infusion will be administered until the skin is closed.

Drug: Tranexamic acid intravenous administration
Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
Other Names:
  • intravenous saline administration
  • Placebo Comparator: placebo group

    The control group will be given intravenous 100 ml of saline

    Drug: Saline
    Participant was given intravenous 100 ml saline
    Other Names:
  • intravenous saline administration
  • Outcome Measures

    Primary Outcome Measures

    1. Visual analog scale, time of first analgesic requirement, used within 24 hours amount of analgesic, [Change from baseline at 0., 6., 12., 24., 48., 72. hours VAS score]

      Investigators will evaluate VAS score, time of first analgesic requirement, used within 24 hours amount of analgesic,

    Secondary Outcome Measures

    1. side effect, 0., 1., 6. hours hemogram value, amount of antiemetic used [Change from baseline at 0., 1., 6. hours]

      Investigators will evaluate demographic characteristics [years, female/male, weight(kg),height(meter), BMI (kg/m2 )], side effect, 0,1,6 st hour hemogram value, amount of antiemetic used.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Elective laparoscopic radical prostatectomy will be performed; Surgeon with more than 10 years of laparoscopic prostatectomy experience

    • Participant BMI(weight/height2)(kg/m2)<35

    • ASA2-3

    • Participant Age>18

    • Participant Age<75

    Exclusion Criteria:
    • Coagulation disorder,

    • Chronic renal failure,

    • Patients allergic to tranexamic acid,

    • Participant Age<18

    • Participant Age>75,

    • Participant BMI(weight/height2)(kg/m2)>35,

    • Surgeon with less than 10 years of laparoscopic prostatectomy experience,

    • Patients who had a cerebral, coronary and thromboembolic event within 6 months before the operation

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Dr. Lutfi Kirdar Kartal Training and Research Hospital

    Investigators

    • Study Director: Gülten Arslan, DrLutfiKirdar training and research hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nihan Yaman Mammadov, MD, principal investigator, Dr. Lutfi Kirdar Kartal Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT06040853
    Other Study ID Numbers:
    • traneksamicanalgesia
    First Posted:
    Sep 18, 2023
    Last Update Posted:
    Sep 18, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 18, 2023